НовостиBenzingaBaird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14 Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14 Benzinga 2026.10.14 09:20 (GMT+0) Открыть на Benzinga Другие новости